What Is Rucaparib (Rubraca)? FDA Approval, Licensing in Turkey, and Reimbursement
Reading tools
In this article
Rucaparib (Rubraca):
Rucaparib (Rubraca®)is a potent PARP inhibitor that targets cellular DNA repair through "synthetic lethality," particularly in BRCA-mutated ovarian and prostate cancers. Its full FDA approval on December 17, 2025, represented the highest level of regulatory recognition of its clinical efficacy.
Drug Profile
- Brand Name: Rubraca®
- Active Ingredient: Rucaparib (rucaparib camsylate)
- Class: PARP (poly ADP-ribose polymerase) inhibitor
- Route of Administration: Oral film-coated tablets
- Manufacturer: Clovis Oncology, Inc.
🇹🇷 Status in Turkey (Licensing and Reimbursement):
- Licensing: Not yet licensed in Turkey.
- Access: It is on the Turkish Ministry of Health's "Overseas Medicine Supply" list and may be imported through the Turkish Pharmacists' Association (TEB) with personal-use authorization.
- Reimbursement: It is not covered by SGK reimbursement; patients obtain it through individual applications.
FDA Approval History
📅 December 19, 2016: Accelerated approval for advanced BRCA-mutated ovarian cancer after 2+ platinum treatments.
📅 April 6, 2018: Approval for maintenance treatment of recurrent ovarian, fallopian tube, or peritoneal cancer.
📅 May 15, 2020: Accelerated approval for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
📅 December 17, 2025 (CURRENT): TRITON3 supported FULL FDA APPROVAL for the mCRPC indication. This approval established rucaparib's superiority over standard treatments.
Mechanism of Action and Resistance
🔬 Molecular Mechanism
Rucaparib inhibits PARP1, PARP2, and PARP3. PARP enzymes repair single-strand DNA breaks. Inhibiting these enzymes causes the breaks to become double-strand breaks during DNA replication. BRCA-mutated cells cannot repair this extensive damage and undergo apoptosis (programmed cell death). This is called Synthetic Lethality .
⚠️ Mechanisms of Resistance
- Restoration of BRCA Function: The cell develops an additional mutation that corrects the original mutation, restoring the repair pathway.
- PARP Mutations: Structural changes in PARP1 prevent drug binding.
- Alternative Repair Pathways: The cell activates more error-prone pathways, such as NHEJ, that nevertheless allow survival.
- Efflux Pumps: Increased proteins such as P-glycoprotein remove the drug from the cell.
Pharmacokinetic Properties
| Property | Clinical Data |
|---|---|
| Absorption | Oral absorption is good. Maximum blood levels (Cmax) are reached in 1.5–6 hours. |
| Distribution | It has a large volume of distribution. Plasma protein binding is 70%. |
| Metabolism | It is broken down in the liver through carboxylation and glucuronidation. CYP enzyme interactions are relatively limited. |
| Elimination | 70% in feces, 30% in urine. Its 17-hour half-life requires twice-daily dosing. |
Adverse Effects
Most patients experience at least one adverse effect during rucaparib treatment. The rates reported in clinical trials are listed below:
• Fatigue/Asthenia: 70%
• Nausea: 64%
• Anemia: 43%
• Vomiting: 38%
• Elevated ALT/AST: 36%
• Decreased Appetite: 31%
• Dysgeusia (Altered Taste): 30%
• Constipation: 27%
• Diarrhea: 22%
• Thrombocytopenia: 21%
• Neutropenia: 20%
• Dizziness: 18%
• Abdominal Pain: 15%
• Headache: 13%
• Back/Muscle Pain: 12%
• Urinary Tract Infection: 10%
• Elevated Creatinine: 9%
• Rash/Itching: 8%
• Photosensitivity: 5%
• MDS/AML (Rare): <1%
Special Precautions
⚠️ Clinical Management and Safety Warnings
- Monitoring Hematological Toxicity: Rucaparib can substantially reduce blood counts. A **complete blood count (CBC) should be performed weekly or every two weeks** before treatment and during the initial months. Cytopenias with delayed recovery should prompt investigation for MDS/AML.
- Sun Protection (Photosensitivity): The medicine makes skin highly sensitive to UV radiation. Patients should use high-protection sunscreen (SPF 50+) outdoors and protect their skin with a hat and long sleeves.
- Renal and Liver Monitoring: Serum creatinine and liver enzyme (ALT/AST) elevations are common. They are generally transient, but substantial increases require dose modification.
- Reproductive Health and Pregnancy: Rucaparib is embryotoxic. Effective contraception should be used by women during treatment and for **6 months** after the final dose, and by men for **3 months** afterward.
- Risk of Secondary Cancer: Very rarely, bone marrow-derived MDS or AML may develop. This has generally been reported after prolonged use in patients previously exposed to intensive chemotherapy.
Drug Interactions and Transporters
- CYP Inhibition: It is a weak CYP1A2, CYP2C19, and CYP3A4 inhibitor and may increase blood levels of medicines such as midazolam, simvastatin, and theophylline.
- Transporter Proteins: Rucaparib inhibits BCRP, P-gp, OCT1, and OATP1B1/3 transporters. There is a risk of interaction with medicines eliminated through these pathways, including Digoxin, Metformin, and Rosuvastatin .
- Herbal Supplements: Strong enzyme inducers such as St. John's wort (Hypericum) may reduce the drug's effect and must not be used.
References
- FDA Approved Drugs: Rubraca (rucaparib) Full Prescribing Information (Revised Dec 17, 2025).
- TRITON3: Rucaparib versus Physician’s Choice in Metastatic Castration-resistant Prostate Cancer.
- ARIEL3: Rucaparib maintenance treatment in patients with recurrent ovarian carcinoma.
- Turkish Ministry of Health, TİTCK Guideline on Overseas Medicine Supply.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.